Community-acquired pneumonia: Is it time to shorten the antibiotic treatment?

Expert Review of Anti-Infective Therapy

Volumn 5, Issue 6, 2007, Pages 933-938

  Esposito, Silvano ^a   Fiore, Marco ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Community acquired pneumonia; Guidelines; Short course antimicrobial therapy

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFACLOR; GEMIFLOXACIN; KETOLIDE; MACROLIDE; MICROSPHERE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DISEASE SEVERITY; DRUG CHOICE; HUMAN; MEDICAL SOCIETY; META ANALYSIS; MONOTHERAPY; PRACTICE GUIDELINE; PUBLICATION; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TREATMENT DURATION;

ANTI-BACTERIAL AGENTS; BACTERIA; COMMUNITY-ACQUIRED INFECTIONS; COSTS AND COST ANALYSIS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; HUMANS; PNEUMONIA, BACTERIAL; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 37349115570     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.5.6.933     Document Type: Article

References (57)

1. Bartlett JG, Dowell SF, Mandell LA et al. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin. Infect. Dis. 31, 347-382 (2000).
2. Mandell LA. Epidemiology and etiology of community-acquired pneumonia. Infect. Dis. Clin. N. Am. 18, 761-776 (2004).
3. File TM Jr, Garau J, Blasi F et al. Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia. Chest 125, 1888-1901 (2004).
4. Segreti J, House HR, Siegel RE. Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting. Am. J. Med. 118(7 Suppl.), S21-S28 (2005).
5. File TM Jr. Community-acquired pneumonia. Lancet 362, 1991-2001 (2003).
6. Mills GD, Oehley MR, Arrol B. Effectiveness of β lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis. Br. Med. J. 330, 456 (2005).
7. Niederman MS, Mandell LA, Anzueto A et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am. J. Respir. Crit. Care. Med. 163, 1730-1754 (2001).
8. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 44(Suppl. 2), S27-S72 (2007).
9. Mandell LA, Bartlett JG, Dowell SF et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin. Infect. Dis. 37, 1405-1433 (2003).
10. Mandell LA, Marrie TJ, Grossman RF et al. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin. Infect. Dis. 31, 383-421 (2000).
11. Halm EA, Teirstein AS. Clinical practice. Management of community-acquired pneumonia. N. Engl. J. Med. 347, 2039-2045 (2002).
12. Bjerre LM, Verheij TJ, Kochen MM. Antibiotics for community acquired pneumonia in adult outpatients. Cochrane Database Syst. Rev. CD002109 (2004).
13. Shefet D, Robenshtok E, Paul M, Leibovici L. Empirical atypical coverage for inpatients with community-acquired pneumonia: systematic review of randomized controlled trials. Arch. Intern. Med. 165, 1992-2000 (2005).
14. BTS guidelines for the management of community acquired pneumonia in adults. Thorax 56, IV1-IV64 (2001).
15. Contopoulos-Ioannidis DG, Ioannidis JP, Chew P, Lau J. Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections. J. Antimicrob. Chemother. 48, 691-703 (2001).
16. File TM Jr. Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia. Clin. Infect. Dis. 39(Suppl. 3), S159-S164 (2004).
17. Hopkins S, Williams D. Five-day azithromycin in the treatment of patients with community-acquired pneumonia. Curr. Ther. Res. Clin. Exp. 56, 915-925 (1995).
18. Socan M. Treatment of atypical pneumonia with azithromycin: comparison of a 5-day and a 3-day course. J. Chemother. 10, 64-68 (1998).
19. Mandell LA, File TM Jr. Short-course treatment of community-acquired pneumonia. Clin. Infect. Dis. 37, 761-763 (2003).
20. Kolditz M, Halank M, Hoffken C. Short-course antimicrobial therapy for community-acquired pneumonia. Treat. Respir. Med. 4, 231-239 (2005).
21. Bohte R, Van't Wout JW, Lobatto S et al. Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community acquired pneumonia. Eur. J. Clin. Microbiol. Infect. Dis. 14, 182-187 (1995).
22. Brion JP, Sedallian A, Le Noc P et al. Azithromycin versus josamycin: treatment of 89 acute pneumonia cases. Pathol. Biol. (Paris) 38, 521-525 (1990).
23. Kinasewitz G, Wood RG. Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia. Eur. J. Clin. Microbiol. Infect. Dis. 10, 872-877 (1991).
24. Kobayashi H, Sakayori S, Koike T et al. Clarithromycin-controlled randomized double-blind studies of azithromycin for treatment of pneumonia. Jpn. J. Chemother. 43, 757-774 (1995).
25. O'Doherty B, Muller O. Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Eur. J. Clin. Microbiol. Infect. Dis. 17, 828-833 (1998).
26. Rahav G, Fidel J, Gibor Y, Shapiro M. Azithromycin versus comparative therapy for the treatment of community acquired pneumonia. Int. J. Antimicrob. Agents 24, 181-184 (2004).
27. Rizzato G, Montemurro L, Fraioli P et al. Efficacy of a three day course of azithromycin in moderately severe community-acquired pneumonia. Eur. Respir. J. 8, 398-402 (1995).
28. Schonwald S, Barsic B, Klinar I, Gunjaca M. Three-day azithromycin compared with ten-day roxithromycin treatment of atypical pneumonia. Scand. J. Infect. Dis. 26, 706-710 (1994).
29. Schonwald S, Gunjaca M, Kolacny-Babic L et al. Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias. J. Antimicrob. Chemother. 25(Suppl. A), 123-126 (1990).
30. Sopena N, Martinez-Vazquez C, Rodriguez-Suarez JR et al. Comparative study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of community-acquired pneumonia in adults. J. Chemother. 16, 102-103 (2004).
31. Dunbar LM, Wunderink RG, Habib MP et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin. Infect. Dis. 37, 752-760 (2003).
32. Leophonte P, File T, Feldman C. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Respir. Med. 98, 708-720 (2004).
33. Leophonte P, Choutet F, Gaillat J et al. Efficacy of a ten day course of ceftriaxone compared to a shortened five day course in the treatment of community-acquired pneumonia in hospitalized adults with risk factors. Med. Mal. Infect. 32, 369-381 (2002).
34. Siegel RE, Alicea M, Lee A, Blaiklock R. Comparison of 7 versus 10 days of antibiotic therapy for hospitalized patients with uncomplicated community-acquired pneumonia: a prospective, randomized, double blind study. Am. J. Ther. 6, 217-222 (1999).
35. Tellier G, Niederman MS, Nusrat R et al. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J. Antimicrob. Chemother. 54, 515-523 (2004).
36. File TM Jr, Niederman MS. Antimicrobial therapy of community acquired pneumonia. Infect. Dis. Clin. N. Am. 18, 993-1016 (2004).
37. Restrepo MI, Anzueto A. Antimicrobial treatment of community acquired pneumonia. Clin. Chest Med. 26, 65-73 (2005).
38. Pakistan Multicentre Amoxycillin Short Course Therapy (MASCOT) pneumonia study group. Clinical efficacy of 3 days versus 5 days of oral amoxicillin for treatment of childhood pneumonia: a multicentre double-blind trial. Lancet 360, 835-841 (2002).
39. Agarwal G, Awasthi S, Kabra SK et al. Three day versus five day treatment with amoxicillin for non-severe pneumonia in young children: a multicentre randomised controlled trial. Br. Med. J. 328, 791 (2004).
40. el Moussaoui R, de Borgie CA, van den Broek P et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. Br. Med. J. 332, 1355 (2006).
41. Richter SS, Heilmann KF, Beekmann SE et al. The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations. Clin. Infect. Dis. 40, 225-235 (2005).
42. Karchmer AW. Increased antibiotic resistance in respiratory tract pathogens: PROTEKT US - an update. Clin. Infect. Dis. 39(Suppl. 3), S142-S150 (2004).
43. Doern GV. Antimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumoniae in the United States. Clin. Infect. Dis. 33(Suppl. 3), S187-S192 (2001).
44. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J. Antimicrob. Chemother. 25(Suppl. A), 73-82 (1999).
45. Schrag SJ, Pena C, Fernandez J et al. Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial. JAMA 286, 49-56 (2001).
46. Kardas P. Patient compliance with antibiotic treatment for respiratory tract infections. J. Antimicrob. Chemother. 49, 897-903 (2002).
47. Reyes H, Guiscafre H, Munoz O et al. Antibiotic noncompliance and waste in upper respiratory infections and acute diarrhea. J. Clin. Epidemiol. 50, 1297-1304 (1997).
48. Cunha BA. Antimicrobial therapy of multidrug-resistant Streptococcus pneumoniae, vancomycin-resistant enterococci, and methicillin-resistant Staphyloccus aureus. Med. Clin. North Am. 90, 1165-1182 (2006).
49. Karlowsky JA, Thornsberry C, Jones ME et al. Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002). Clin. Infect. Dis. 36, 963-970 (2003).
50. Davidson R, Cavalcanti R, Brunton JL et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N. Engl. J. Med. 346, 747-750 (2002).
51. Whitney CG, Farley MM, Hadler J et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N. Engl. J. Med.-343, 1917-1924 (2000).
52. Powis J, McGeer A, Green K et al. In vitro antimicrobial susceptibilities of Streptococcus pneumoniae clinical isolates obtained in Canada in 2002. Antimicrob. Agents Chemother. 48, 3305-3311 (2004).
53. Clay KD, Hanson JS, Pope SD et al. Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Ann. Intern. Med. 144, 415-420 (2006).
54. Bartlett JG, Breiman RF, Mandell LA et al. Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America. Clin. Infect. Dis. 26, 811-838 (1998).
55. Mandell LA. Update on community-acquired pneumonia: new pathogens and new concepts in treatment. Postgrad. Med. 118, 35-46 (2005).
56. Li JZ, Winston LG, Moore DH, Bent S. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am. J. Med. 120, 783-790 (2007).
57. Blasi F, Tarsia P. Value of short-course antimicrobial therapy in community-acquired pneumonia. Int. J. Antimicrob. Ag. 26(Suppl. 3), 148-155 (2005).